S&P 500   4,282.91 (+1.47%)
DOW   33,741.37 (+2.06%)
QQQ   354.84 (+0.80%)
AAPL   180.51 (+0.23%)
MSFT   334.20 (+0.49%)
META   274.03 (+0.52%)
GOOGL   125.00 (+1.03%)
AMZN   124.76 (+1.62%)
TSLA   215.99 (+4.08%)
NVDA   394.29 (-0.86%)
NIO   7.71 (+2.25%)
BABA   85.40 (+2.89%)
AMD   118.72 (-0.63%)
T   15.13 (-4.30%)
F   12.42 (+2.56%)
MU   68.77 (-0.46%)
CGC   0.85 (+1.45%)
GE   106.36 (+1.61%)
DIS   91.11 (+2.84%)
AMC   4.56 (+0.22%)
PFE   38.55 (+1.39%)
PYPL   64.28 (+1.95%)
NFLX   404.50 (+0.34%)
S&P 500   4,282.91 (+1.47%)
DOW   33,741.37 (+2.06%)
QQQ   354.84 (+0.80%)
AAPL   180.51 (+0.23%)
MSFT   334.20 (+0.49%)
META   274.03 (+0.52%)
GOOGL   125.00 (+1.03%)
AMZN   124.76 (+1.62%)
TSLA   215.99 (+4.08%)
NVDA   394.29 (-0.86%)
NIO   7.71 (+2.25%)
BABA   85.40 (+2.89%)
AMD   118.72 (-0.63%)
T   15.13 (-4.30%)
F   12.42 (+2.56%)
MU   68.77 (-0.46%)
CGC   0.85 (+1.45%)
GE   106.36 (+1.61%)
DIS   91.11 (+2.84%)
AMC   4.56 (+0.22%)
PFE   38.55 (+1.39%)
PYPL   64.28 (+1.95%)
NFLX   404.50 (+0.34%)
S&P 500   4,282.91 (+1.47%)
DOW   33,741.37 (+2.06%)
QQQ   354.84 (+0.80%)
AAPL   180.51 (+0.23%)
MSFT   334.20 (+0.49%)
META   274.03 (+0.52%)
GOOGL   125.00 (+1.03%)
AMZN   124.76 (+1.62%)
TSLA   215.99 (+4.08%)
NVDA   394.29 (-0.86%)
NIO   7.71 (+2.25%)
BABA   85.40 (+2.89%)
AMD   118.72 (-0.63%)
T   15.13 (-4.30%)
F   12.42 (+2.56%)
MU   68.77 (-0.46%)
CGC   0.85 (+1.45%)
GE   106.36 (+1.61%)
DIS   91.11 (+2.84%)
AMC   4.56 (+0.22%)
PFE   38.55 (+1.39%)
PYPL   64.28 (+1.95%)
NFLX   404.50 (+0.34%)
S&P 500   4,282.91 (+1.47%)
DOW   33,741.37 (+2.06%)
QQQ   354.84 (+0.80%)
AAPL   180.51 (+0.23%)
MSFT   334.20 (+0.49%)
META   274.03 (+0.52%)
GOOGL   125.00 (+1.03%)
AMZN   124.76 (+1.62%)
TSLA   215.99 (+4.08%)
NVDA   394.29 (-0.86%)
NIO   7.71 (+2.25%)
BABA   85.40 (+2.89%)
AMD   118.72 (-0.63%)
T   15.13 (-4.30%)
F   12.42 (+2.56%)
MU   68.77 (-0.46%)
CGC   0.85 (+1.45%)
GE   106.36 (+1.61%)
DIS   91.11 (+2.84%)
AMC   4.56 (+0.22%)
PFE   38.55 (+1.39%)
PYPL   64.28 (+1.95%)
NFLX   404.50 (+0.34%)
NASDAQ:OPNT

Opiant Pharmaceuticals (OPNT) News Today

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$20.03
▼
$21.10
52-Week Range
N/A
Volume
562,700 shs
Average Volume
77,920 shs
Market Capitalization
$108.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media
Get Opiant Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter.



OPNT Media Mentions By Week

OPNT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

OPNT
News Sentiment
▼
0.00

0.49
▲
Average
Medical
News Sentiment

OPNT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

OPNT Articles
This Week
▼
0

0
▲
OPNT Articles
Average Week

SourceHeadline
msn.com logoUPDATE 2-US FDA approves Opiant's spray for reversing opioid-related overdoses
msn.com - May 24 at 10:52 AM
msn.com logoREFILE-US FDA approves Opiant's overdose reversal spray
msn.com - May 23 at 8:46 AM
msn.com logoIndivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science Portfolio
msn.com - March 3 at 5:24 PM
marketbeat.com logo
marketbeat.com - March 2 at 6:00 AM
finance.yahoo.com logoOpiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) largest shareholders are individual investors with 52% ownership, institutions own 33%
finance.yahoo.com - February 22 at 10:44 AM
finance.yahoo.com logoOpiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC
finance.yahoo.com - February 7 at 8:53 PM
seekingalpha.com logoHorizon Pharma, Opiant fall amid Elizabeth Warren concern about pharma deals (update)
seekingalpha.com - January 26 at 7:17 PM
finance.yahoo.com logoOpiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
finance.yahoo.com - January 19 at 8:13 PM
thetimes.co.uk logoDechra Pharmaceuticals defies cooling pets market
thetimes.co.uk - January 14 at 8:18 PM
seekingalpha.com logoOpiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown In
seekingalpha.com - January 13 at 6:24 PM
marketbeat.com logoOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT) CEO Sells $23,896.60 in Stock
marketbeat.com - January 9 at 6:33 PM
businesswire.com logoOPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant ...
businesswire.com - January 7 at 6:45 PM
marketbeat.com logoOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Short Interest Update
marketbeat.com - December 28 at 7:44 PM
marketbeat.com logoOpiant Pharmaceuticals (NASDAQ:OPNT) Cut to "Market Perform" at Northland Securities
marketbeat.com - November 23 at 8:29 AM
finance.yahoo.com logoOpiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose
finance.yahoo.com - November 22 at 4:08 PM
marketbeat.com logoOppenheimer Comments on Opiant Pharmaceuticals, Inc.'s FY2022 Earnings (NASDAQ:OPNT)
marketbeat.com - November 17 at 7:52 AM
benzinga.com logoOPNT Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Opiant Pharmaceuticals
benzinga.com - November 15 at 6:58 AM
benzinga.com logoEQUITY ALERT: The M&A Class Action Firm Announces the Investigation of Opiant Pharmaceuticals, Inc. - OPNT
benzinga.com - November 15 at 6:58 AM
benzinga.com logoShareholder Alert: Ademi LLP investigates whether Opiant Pharmaceuticals Inc. has obtained a Fair Price in its transaction with Indivior
benzinga.com - November 14 at 12:18 PM
benzinga.com logoOPNT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Opiant Pharmaceuticals, Inc. Is Fair to Shareholders
benzinga.com - November 14 at 12:18 PM
nasdaq.com logoIndivior To Buy Opiant For $145 Mln In Cash
nasdaq.com - November 14 at 7:17 AM
seekingalpha.com logoOpiant surges 123% as Indivior set to acquire overdose therapy maker for $145M
seekingalpha.com - November 14 at 7:17 AM
marketwatch.com logoOpiant Pharmaceuticals Shares Surge Premarket on Takeover by Indivior >OPNT
marketwatch.com - November 14 at 7:17 AM
finance.yahoo.com logoIndivior PLC to Acquire Opiant Pharmaceuticals
finance.yahoo.com - November 14 at 7:17 AM
finance.yahoo.com logoOpiant Pharmaceuticals Announces Third Quarter 2022 Financial Results
finance.yahoo.com - November 14 at 7:17 AM
finance.yahoo.com logoNarcan Owner Opiant to Be Acquired by Indivior for $145 Million
finance.yahoo.com - November 14 at 2:17 AM
finance.yahoo.com logoThe past five years for Opiant Pharmaceuticals (NASDAQ:OPNT) investors has not been profitable
finance.yahoo.com - November 2 at 11:16 AM
finance.yahoo.com logoOpiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022
finance.yahoo.com - October 27 at 7:32 PM
finance.yahoo.com logoOpiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder
finance.yahoo.com - October 6 at 1:23 PM
marketwatch.com logoINVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Opiant Pharmaceuticals, Inc. for Potential Breach of Fiduciary Duty Claims
marketwatch.com - October 5 at 12:00 PM
finance.yahoo.com logoOpiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis Syndrome
finance.yahoo.com - August 22 at 5:33 PM
finance.yahoo.com logoAnalysts Just Shaved Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts Dramatically
finance.yahoo.com - August 13 at 9:16 AM
finance.yahoo.com logoOpiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update
finance.yahoo.com - August 11 at 4:27 PM
finance.yahoo.com logoOpiant Pharma Secures Additional BARDA Funding For Opioid Overdose Treatment
finance.yahoo.com - August 9 at 12:09 PM
finance.yahoo.com logoOpiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal Nalmefene
finance.yahoo.com - August 8 at 8:53 PM
nasdaq.com logoOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT) insiders sold US$871k worth of stock, possibly signalling a downtrend
nasdaq.com - August 4 at 2:16 PM
finance.yahoo.com logoOpiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent With Claims Covering OPNT003 for the Treatment of Opioid Overdose
finance.yahoo.com - August 2 at 8:58 PM
finance.yahoo.com logoOpiant Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022
finance.yahoo.com - August 1 at 8:17 PM
finance.yahoo.com logoA Look At The Fair Value Of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)
finance.yahoo.com - June 9 at 11:58 AM
finance.yahoo.com logoOpiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene
finance.yahoo.com - June 8 at 8:56 PM
finance.yahoo.com logoOpiant Pharmaceuticals Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose
finance.yahoo.com - June 1 at 9:05 PM
finance.yahoo.com logoOpiant Pharmaceuticals to Hold Virtual 2022 Annual Shareholder Meeting on Tuesday, June 14, 2022 at 9:00am PDT
finance.yahoo.com - May 20 at 8:38 PM
seekingalpha.com logoOpiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com - May 14 at 10:14 PM
marketbeat.com logo
marketbeat.com - May 13 at 9:40 AM
marketbeat.com logo
marketbeat.com - May 13 at 9:32 AM
finance.yahoo.com logoOPNT: Positive Results for Pharmacodynamic Trial of OPNT003…
finance.yahoo.com - May 12 at 1:46 PM
marketbeat.com logo
marketbeat.com - May 11 at 1:03 PM
ca.investing.com logoOpiant Pharmaceuticals Posts Wider Q1 Loss
ca.investing.com - May 10 at 7:23 PM
finance.yahoo.com logoOpiant Pharmaceuticals' (NASDAQ:OPNT) investors will be pleased with their solid 195% return over the last five years
finance.yahoo.com - May 9 at 3:36 PM
finance.yahoo.com logoOpiant Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 10, 2022
finance.yahoo.com - May 3 at 3:41 PM
Get Opiant Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:OPNT) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -